The reversible airway hyper-reactivity (AHR) of asthma is modeled by sensitizing and challenging mice with aerosolized ovalbumin. However the C57BL/6 murine strain does not display the large increase in circulating IgG and IgE antibodies found in human atopy and asthma. We found that commercial ovalbumin was contaminated with LPS in amounts sufficient to fully activate endothelial cells in an in vitro assay of the first step of inflammation. Desensitization of TLR4 by LPS pretreatment suppressed the inflammatory effect of ovalbumin. The presence of LPS was occult because it does not require serum presentation and, like the LPS of Salmonella minnesota, was not suppressed by polymyxin B. Purified ovalbumin did not activate endothelial cells in vitro; however endotoxin-free ovalbumin was far more effective than commercial material in stimulating IgE production and respiratory dysfunction in a C57/BL6 murine model of AHR. Moreover, endotoxin-free ovalbumin induced lung inflammation with alveolar enlargement and destruction in a histologic pattern that differed from the changes caused by commercial, endotoxin-contaminated ovalbumin. Reconstitution of purified ovalbumin with Salmonella minnesota LPS decreased lung inflammation, decreased changes in lung function, and suppressed anti-ovalbumin antibody concentrations. We conclude endotoxin contaminates ovalbumin preparations, and that endotoxin co-administration with the ovalbumin antigen creates a state of tolerance in a murine model of AHR. Co-exposure to endotoxin and antigen occurs in humans through organic dusts, so murine models of AHR may reflect the clinical situation, but models based on commercial ovalbumin do not accurately reflect the effect of protein antigen alone on animal physiology.
aerosol challenge. Why exposure to ovalbumin would mirror changes wrought by endotoxin is unknown.
Ovalbumin has long been employed as a model immunogen as a single antigen to reduce the complexity of modeling AHR. Ovalbumin induces IgE accumulation in the serum of mice, although there is a significant variation in the amount and antibody class among strains (12, 13) , and at least in BALB/c mice anti-ovalbumin IgE injection alone induces AHR (14) . We find, however, that commercial preparations of ovalbumin are highly contaminated with an inflammatory endotoxin that was not sequestered by polymyxin B treatment. We purified large amounts of ovalbumin to an endotoxin-free state and then examined how co-administration of an inflammatory and immunologic trigger, a likely scenario outside the laboratory setting, affects the development of AHR in a murine model of this disease. We report that co-administration of endotoxin with the ovalbumin immunogen suppresses changes in lung function, alters lung pathology, and immunoglobin production.
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Results
Commercial ovalbumin is inflammatory-Inflammation is initiated and localized by
activation of endothelium (21) . LPS stimulates endothelial cells via TLR4 receptors, and induces expression of TLR2 receptors that respond to other endotoxins including bacterial lipoproteins (22) . We used human umbilical vein endothelial cells to probe for pro-inflammatory material by treating these cells for 4 h with buffer containing either human serum albumin or chicken ovalbumin before their state of activation was assessed by overlaying the monolayer with quiescent human PMN (23). Pyrogen-free human serum albumin did not induce endothelial cell-dependent PMN adhesion (Figure 1 ), but even low concentrations of ovalbumin proved to be equivalent to phorbol myristate acetate (PMA) or E. coli LPS in stimulating endothelial cells. The response of endothelial cells to E. coli LPS is enhanced by the LPS-binding protein and soluble CD14 of serum, and serum similarly potentiated the response to low concentrations of ovalbumin. Higher concentrations of ovalbumin, however, did not require these accessory proteins.
LPS-like material is present in commercial ovalbumin, but cannot easily be suppressed
by polymyxin B-Resolution of commercial ovalbumin by SDS-PAGE and staining with a periodate-Schiff reaction showed the presence of material with the characteristics of LPS (not shown), so we assessed the endotoxic content of this ovalbumin with a Limulus amebocyte lysate assay. We found that as little as 3 mg/ml of ovalbumin contained about 0.5 EU/ml of endotoxic activity (Figure 2A ). This is a considerable amount of endotoxin, but since we do not know its identity we cannot calculate its mass in the absence of an appropriate standard. However extrapolating from the LPS of E. coli, we estimate that 1 mg of this batch of ovalbumin could be contaminated with as much as 10 mg of LPS.
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We tested whether the inflammatory material in commercial ovalbumin was the endotoxic contaminant we quantified in the Limulus assay. For this we pretreated, or not, each of the agonists with polymyxin B, an antibiotic that sequesters LPS. We found ( Figure 2B ) that polymyxin B abolished the stimulation of endothelial cells by our positive control, E. coli LPS, whereas it was only partially effective at this concentration when mixed with even low concentrations of ovalbumin. In this experiment we used a submaximal amount of ovalbumin (3 µg/ml) to be sure that the ratio of polymyxin B to endotoxin was high, but even so polymyxin B was ineffective in neutralizing the endothelial cell agonist(s).
LPS from Salmonella minnesota is resistant to polymyxin B sequestration and does not
require CD14 presentation-Chicken eggs can be contaminated with Salmonella and the TLR4 receptor responds to the endotoxin of this bacteria as it does to that of E. coli (24), so we determined whether Salmonella LPS differed from E. coli LPS as a target for polymyxin B sequestration. To test this, LPS from the two bacteria was pretreated with polymyxin B and endothelial cell activation was assayed in serum-containing medium in the continued presence of polymyxin B. E. coli LPS became inflammatory in this assay at
We determined whether the effect of Salmonella LPS on endothelial cells-like that of E. coli-was enhanced by the presence of serum and the soluble CD14 (sCD14) it contains (25). We preincubated endothelial cells in the presence or absence of serum, or with the blocking anti-CD14 monoclonal antibody MY4. The serum-supplied sCD14 was important at low concentrations of E. coli LPS because MY4 completely inhibited endothelial cell activation at LPS concentrations of 100 µg/ml and below ( Figure 3C ).
Above this concentration, the response to E. coli LPS became both serum-and CD-14 independent. In contrast, activation of endothelial cells by Salmonella LPS was only partially dependent on serum and sCD14, and only at low LPS concentrations. The LPS of Salmonella ( Figure 3D ) displays several of the characteristics of the biologically active material in purchased ovalbumin in that it is potent, largely independent of serum, and minimally affected by polymyxin B. 
Contamination of commercial ovalbumin accounts for its inflammatory effects-We
purified large amounts of ovalbumin from fresh eggs to find that the purified ovalbumin-in marked contrast to the starting material-was without effect on endothelial cell monolayers ( Figure 5 ). The presence of serum did not increase the sensitivity of the cells to purified ovalbumin, which it did for low -and not highamounts of commercial ovalbumin. We added Salmonella LPS to the purified ovalbumin and found that this combination behaved as higher concentrations of commercial ovalbumin: there was high basal activity that was insensitive to the presence of serum, polymyxin B or anti-CD14 MY4 antibody. We noted that ovalbumin enhanced the effect of Salmonella LPS over free LPS (compare the unfilled bars of the rightmost two groups of columns), but we have no direct evidence that ovalbumin aids in the presentation of LPS to endothelial cells.
Ovalbumin contamination affects development of murine AHR-Commercial ovalbumin
has been widely used as an antigen in murine models of airway hyper-responsiveness (AHR). We determined whether purified ovalbumin, in the absence of a concomitant inflammatory signal from contaminating endotoxin, induced AHR, and whether the addition of Salmonella LPS to this endotoxin-free material recapitulated the results obtained with commercial ovalbumin. Mice were sensitized on day 0 with either endotoxin-free PBS, purified ovalbumin, ovalbumin reconstituted with Salmonella LPS, commercial ovalbumin or Salmonella LPS alone. These mice were then exposed to these same agents in an aerosolized form on day 8 and then every day for 9 days starting on day 14 as described (11,28). To detect AHR, the breathing patterns of these mice were analyzed on days 15, 18, 22 of the protocol in awake unrestrained animals by plethysmography-to calculate the Penh variable-just after each mouse was challenged with methacholine.
Mice challenged with commercial ovalbumin developed small changes-about two fold-in their airway reactivity ( Figure 6 ) by day 22 when challenged with by guest on November 19, 2017 http://www.jbc.org/ Downloaded from minimally effective dose of methacholine (15 mg/ml). We tested purified, endotoxin-free ovalbumin in this model, but unexpectedly found that this proved to be significantly better at sensitizing the mice than the commercial material. By example, as early as day 18 mice sensitized with the endotoxin-free ovalbumin responded to the methacholine challenge-and this response was greatly increased by day 22 of the model. Salmonella LPS alone, when used at a concentration giving a response equivalent to commercial ovalbumin in the Limulus amebocyte assay, did not differ in its effects from the vehicle control. We then combined this amount of Salmonella LPS with purified ovalbumin to find that this combination suppressed the effect of the purified protein in sensitizing the mice to the methacholine challenge. The combination of Salmonella LPS and endotoxinfree ovalbumin therefore behaved much as the purchased protein preparation. We conclude that endotoxin can be a powerful negative modulator in the development of AHR in this model.
Lung inflammation and structural changes induced by purified and commercial
ovalbumin-We examined lung sections from mice subjected to the AHR model to find that the sections from PBS-exposed control mice were unremarkable ( Figure 7A ). In contrast, sections from mice sensitized and challenged with either purified or commercial ovalbumin showed distinct-and non-equivalent-changes over time. Lung consolidation was evident in animals receiving purified ovalbumin (note the overall increase in tissue staining), but this was not a prominent feature of mice receiving commercial ovalbumin. Enlargement ( Figure 7B ) of the areas outlined in Figure 7A Adhesion of leukocytes to endothelial cells is an initial step in the inflammatory response to endotoxin, and so we used these cells to probe for bioactivity. We found endothelial cells to be fully activated by a few micrograms of commercial ovalbumin, where we estimate-based on the Limulus amebocyte assay-that as much as 1% of the mass may be endotoxin. The response of the LAL assay varies with the nature of the LPS being analyzed, so we lack an appropriate standard to accurately define its mass in ovalbumin. A recent publication (30) also detected endotoxic activity in ovalbumin solutions, although at levels less than we measured, that did not affect the development of lung disease in BALB/c mice. Also in BALB/c mice, addition of low levels of LPS induces an IgE-promoting Th2-type response while higher amounts of LPS induce a Th1 by guest on November 19, 2017 http://www.jbc.org/ Downloaded from response (31). This study, unlike most murine models of AHR, did not use alum as an adjuvant so this may account for the difference we find in a model using C57/Bl6 mice, but there also are large differences in the response to ovalbumin among inbred strains of mice (32). Among these differences is the very low production of ovalbumin-specific IgE antibody by C57/BL6 mice relative to BALB/c mice (32), although we show here that the presence of contaminating endotoxin in ovalbumin significantly suppresses the production of these antibodies in C57/BL6 mice. by guest on November 19, 2017 
